Tel Aviv (October 15, 2019) – BioLight is pleased to announce that its subsidiary, DiagnosTear Ltd. (“DiagnosTear“), that is engaged in research, development and commercialization of a product that is based on DiagnosTear’s TeaRx ™ technology, which is used to diagnose, personalize treatment and monitor dry eye syndrome by examining the composition of the tear film (“Diagnostear Product” and the “TeaRx ™ technology”), announced that it received an approval to register a patent from the United States Patent and Trademark Office (USPTO) (the “Patent“).
 Holding via XL Vision Sciences Ltd. (wholly owned subsidiary) approx. 89% of the issued and share capital of Diagnostear (approx. 86% fully diluted).
Link to Newsroom